Lanadelumab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

COVID-19PneumoniaKidney DiseaseHereditary AngioedemaAngioedema

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

1

Lanadelumab

Takeda

Phase 3

22

Aldactone

Pfizer

Preclinical

13

Calciferol

Alnylam Pharmaceuticals

Preclinical

—4

Nitrostat

VViatris Specialty LLC

Preclinical

15

Nadroparin

GSK

Preclinical

16

Orap

Teva

Preclinical

17

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

38

Conventional

PPopulation Health Research Institute

Preclinical

19

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

110

DAS181

AAnsun Biopharma, Inc.

Preclinical

4Show 12 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hereditary Angioedema5 trials

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

Completed·Takeda·Phase 3·NCT04070326·21 enrolled

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Completed·Takeda·Phase 3·NCT05460325·20 enrolled

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Completed·Takeda·Phase 3·NCT04180163·12 enrolled

Show 2 more trials

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Completed·Takeda··NCT05397431·155 enrolled

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No longer available·Takeda··NCT04583007

Angioedema3 trials

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed·Takeda·Phase 3·NCT04444895·73 enrolled

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Completed·Takeda·Phase 3·NCT04206605·77 enrolled

Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

Recruiting·—·Phase 4·NCT06818474·5 enrolled

COVID-192 trials

Lanadelumab for Treatment of COVID-19 Disease

Completed·RRadboud University Medical Center·Phase 1/2·NCT04422509·43 enrolled

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Completed·Amgen·Phase 3·NCT04590586·515 enrolled

LAM1 trial

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)

Unknown status·—·Phase 2·NCT04278885·4 enrolled

Injury1 trial

Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

Active, not recruiting·—·Phase 1·NCT04848272·48 enrolled

4 more indications

Pneumonia1 trial

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

Withdrawn·Takeda·Phase 1·NCT04460105

Adult Subject1 trial

Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects

Completed·Takeda·Phase 1·NCT03401671·32 enrolled

Intravenous1 trial

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

Completed·Takeda·Phase 1·NCT04503603·12 enrolled

Hemodialysis Complication1 trial

Prevention of Dialysis-Induced Hypotension by Inhibiting Plasma Kallikrein

Completed·VVanderbilt University Medical Center·Phase 2·NCT05297786·28 enrolled

Details

Drug Info

Related News